One in nine women will develop breast cancer during their lifetime and most of these women will be postmenopausal. Across this demographic, 75% of the breast cancers are hormone receptor (HR) positive and therefore will be treated with hormonal therapy. However, given the wealth of clinical ...
The post-screening management options are already well-defined by NICE guidelines [3]. All women, independent of risk, should receive lifestyle advice, with all those at moderate or high risk of breast cancer offered risk-reducing medication and enhanced breast cancer screening/surveillance dependent...
early and locally advanced breast cancer: diagnosis and treatment ( clinical guideline 80 ) NICE, National Institute for Clinical Excellence (2009) Early and locally advanced breast cancer: diagnosis and treatment. NICE: London... Correspondence,Jnci 被引量: 0发表: 0年 Prevalence of Posttraumatic ...
Breast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating solutions into practice. Methods More than 100 internationally recogn...
While new strategies for the treatment of invasive breast cancer (BC) are emerging, radiotherapy (RT) modalities are still under debate. The French expert review board of Nice-Saint-Paul de Vence was asked firstly to conduct a qualitative evidence-based systematic review and then to establish cli...
Predictions based on UK breast cancer incidence. Full size image Table 1 Predicted distributions of women in the population in different risk categories (based on NICE guidelines3) Full size table As expected, the variation in risk is greatest when including all RFs in the model (light blue ...
NICE recommends Oncotype DX to guide breast cancer therapy . .Health-policyMyelofibrosis, treatmentReimbursementRuxolitinib, therapeutic useSplenomegaly, treatmentIn the same guidance the routine use of three other tests − the IHC4, MammaPrint or Mammostrat − was not supported. However, NICE ...
The UK’s NICE has recommended Eli Lilly’s abemaciclib as an option for adults with HR+, HER2- breast cancer which has spread to other parts.
The audit used a validated family history questionnaire and risk assessment tool as a screening approach for identifying and grading familial risk in line with the NICE guidelines, to guide referral to the familial cancer screening service. The response rate to family history questionnaires was 54% ...
Preventive cancer screening and general reproductive services were uniformly available at all centers, although DHHS centers offered extensive reproductive services on-site more frequently, and VA centers more often had on-site mental health... B Bean-Mayberry,EM Yano,N Bayliss,... - 《Journal of...